EFFECT OF A PPAR-A AGONIST ON THE AGE RELATED CHANGES IN MYOCARDIAL METABOLISM

PPAR-A 激动剂对年龄相关的心肌代谢变化的影响

• 批准号: 7603369
• 负责人: Robert J. Gropler
• 金额: $ 0.47万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603369
• 关键词: Aging; Agonist; Cardiac; Cardiovascular Diseases; Catabolism; Computer Retrieval of Information on Scientific Projects Database; Diabetes Mellitus; Disease; Elderly; Funding; Gemfibrozil; Grant; Heart failure; Hypertension; Institution; Lipids; Measures; Metabolism; Myocardial; Play; Positron; Pump; Relative (related person); Reliance; Research; Research Personnel; Resources; Role; Source; Structure; Testing; United States National Institutes of Health; age related; fatty acid oxidation; glucose metabolism; heart function; innovation; mortality; normal aging; oxidation; receptor; tomography

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cardiovascular disease is a leading cause of mortality in the elderly. Normal aging is associated with changes in structure and function of heart that exacerbate changes associated with diseases such as diabetes hypertension and heart failure that are common in the elderly. We have shown aging associated with a relative decline in lipid catabolism and higher reliance on glucose metabolism to support the pump function. Perxisome proliferator activated receptor (PPAR) alpha plays an important role in cardiac fatty acid oxidation. We hypothesize that aging associated changes in PPAR alpha contribute significantly to changes in lipid utilization. In this innovative project we will test whether treatment of a healthy older group with PPAR a agonist gemfibrozil would result in partial reversal of aging associated decline in cardiac lipid oxidation measured by positron emmision tomography

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 心血管疾病是老年人死亡的主要原因。 正常衰老与心脏结构和功能的变化有关，这些变化加剧了与老年人常见的糖尿病、高血压和心力衰竭等疾病有关的变化。 我们已经表明，衰老与脂质代谢的相对下降和对葡萄糖代谢的更高依赖性有关，以支持泵功能。 过氧化物酶体增殖物激活受体（Perxisome proliferator activated receptor，PPAR）α在心肌脂肪酸氧化中起重要作用。我们推测，与衰老相关的过氧化物酶体增殖物激活受体α的变化对脂质利用的变化有重要作用。 在这个创新的项目中，我们将测试用过氧化物酶体增殖物激活受体激动剂吉非罗齐治疗一个健康的老年组是否会导致部分逆转衰老相关的心脏脂质氧化下降，通过正电子发射断层扫描测量